In other words, monitoring the levels of cryptic proteins in patient samples could address one of the longest standing challenges in the ALS and FTD field: how to detect and monitor TDP‐43 pathobiological burden in vivo. Here, TARDBP is linked to amyotrophic lateral sclerosis.